Retatrutide Benefits and Phase 3 Clinical Trial Results

What Retatrutide Does Across Three Hormone Receptors

Retatrutide is an investigational triple hormone receptor agonist that stimulates the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. In metabolic research, medications that target multiple receptors are categorized by the specific endocrine pathways they engage. Single-target agents focus solely on GLP-1 receptors.

Dual-target therapies activate both GLP-1 and GIP receptors, as analyzed in our comparison of semaglutide vs tirzepatide vs retatrutide. Retatrutide adds glucagon receptor activation to establish a three-receptor profile.

Because retatrutide engages three separate receptors, popular news reports sometimes label retatrutide as a GLP-3 therapy. GLP-3 is not a real hormone. The phrase is an informal media shorthand rather than an official regulatory classification, as explained in our guide on what GLP-3 means.

Current Approval Status and TRIUMPH Clinical Trials

Retatrutide is an investigational agent that does not have FDA approval for any clinical use in the United States. Eli Lilly is evaluating retatrutide in a multi-study Phase 3 clinical development program designated as TRIUMPH.

Eli Lilly announced that additional Phase 3 readouts from TRIUMPH-2 and TRIUMPH-3 would be shared later in 2026. That announcement did not specify a date for regulatory submission to the FDA. Formal review begins only after the manufacturer submits completed trial packages.

Retatrutide is not currently available for medical use. Patients who require treatment for obesity or metabolic conditions today cannot obtain retatrutide through standard medical channels. Anyone seeking active medical therapy today should speak with a licensed clinician rather than an unverified online source.

Retatrutide Weight Loss Results in Phase 3 Trials

In the Phase 3 TRIUMPH-1 clinical trial, adults with obesity taking retatrutide achieved an average weight reduction of up to 28.3 percent at 80 weeks. Eli Lilly published these top-line findings in an announcement on the Phase 3 TRIUMPH-1 trial, which enrolled 2,339 adult participants without type 2 diabetes. Each participant was randomly assigned to one of three retatrutide doses (4 mg, 9 mg, or 12 mg) or a placebo.

Weight reduction followed a direct dose-response relationship across the 80-week study period. Participants receiving the 4 mg dose lost an average of 19.0 percent of baseline weight, or roughly 47.2 pounds. The 9 mg cohort achieved an average loss of 25.9 percent, which equals about 64.4 pounds.

Participants on the highest dose of 12 mg lost an average of 28.3 percent of their starting weight, or approximately 70.3 pounds. By contrast, participants in the placebo group lost an average of 2.2 percent, or about 5.5 pounds. The difference was substantial.

Across these Phase 3 investigations, a higher assigned dose consistently produced greater total weight reduction. The 12 mg dose produced the highest average weight loss in each evaluated clinical population. These figures represent trial averages.

Retatrutide Trial Results in Type 2 Diabetes

Adults with type 2 diabetes enrolled in the TRIUMPH-2 study lost an average of up to 20.8 percent of baseline body weight over 80 weeks. The trial tracked the same three doses used in TRIUMPH-1.

In TRIUMPH-2, participants taking the 4 mg dose of retatrutide achieved an average weight reduction of 12.7 percent at 80 weeks. Those assigned to the 9 mg dose reached an average weight loss of 19.1 percent. Participants taking the 12 mg dose recorded an average reduction of 20.8 percent, compared to 4.0 percent among placebo recipients.

These findings show how retatrutide performed in a population with established type 2 diabetes. We present the TRIUMPH-2 data alongside TRIUMPH-1 to illustrate how trial results varied across separate diagnostic cohorts.

Cardiometabolic Retatrutide Benefits in Phase 3 Trials

Beyond total weight loss, retatrutide produced statistically significant improvements across several cardiovascular risk factors in the TRIUMPH-1 study. At 80 weeks, 65.3 percent of participants receiving the 12 mg dose achieved a body mass index (BMI) under 30. That benchmark shifts an individual below the clinical threshold for obesity.

TRIUMPH-1 also demonstrated statistically significant reductions from baseline compared to placebo across five specific health indicators. Waist circumference decreased, reflecting a reduction in central abdominal girth. Systolic blood pressure dropped in participants taking retatrutide.

Non-HDL cholesterol, which measures total atherogenic particles in the bloodstream, showed measurable reductions compared with placebo. Circulating triglycerides, another lipid marker monitored during routine cardiovascular evaluations, also improved compared to placebo. The trial measured high-sensitivity C-reactive protein (hsCRP) to track systemic inflammation.

In TRIUMPH-1, hsCRP levels declined in participants assigned to retatrutide relative to placebo. Clinicians monitor hsCRP because lower values indicate reduced systemic inflammation.

Evidence in Knee Osteoarthritis Populations

The Phase 3 TRIUMPH-4 clinical trial evaluated retatrutide specifically in adults diagnosed with obesity and knee osteoarthritis. Participants taking the 12 mg dose achieved an average weight loss of 28.7 percent at 68 weeks. That figure comes from TRIUMPH-4 alone, a single trial in that specific population.

Eli Lilly reported body weight results for the TRIUMPH-4 trial population without releasing specific joint symptom measurements. The available data set does not include numerical outcomes for knee pain scores, stiffness ratings, or functional mobility indices. Eli Lilly has not published those secondary measures yet.

Whether retatrutide directly alleviates clinical osteoarthritis pain remains unconfirmed until detailed secondary readouts are published. Full study publications will clarify symptom changes.

Health Outcomes Not Established in Current Data

Published clinical trials for retatrutide have not evaluated outcomes for chronic kidney disease, obstructive sleep apnea, or low back pain. Some online articles suggest retatrutide provides benefits for these conditions by pointing to other incretin therapies. Retatrutide's own trial data does not verify that.

None of those outcomes are part of retatrutide's published trial data. The evidence does not exist yet.

What would change our answer is the publication of completed clinical trials designed specifically to measure these clinical endpoints. If future data from TRIUMPH-3 or specialized sub-studies demonstrate positive outcomes for renal or respiratory health, we will update our coverage accordingly. For now, those benefits remain unproven.

What Retatrutide Means for You Right Now

Phase 3 trial data confirms that retatrutide produces substantial weight loss alongside measurable improvements in several cardiometabolic markers. At the same time, retatrutide remains an investigational drug awaiting full safety and efficacy reviews from regulatory authorities.

Patients looking to improve metabolic health cannot obtain retatrutide today because it is not commercially available. If you are managing obesity, elevated blood pressure, or blood sugar concerns, a primary healthcare physician remains the right first call for what is available to you today.

When you discuss retatrutide benefits with a doctor, focus on what published trial data proves while waiting for regulatory agencies to complete their reviews. Staying informed on emerging research helps you make thoughtful decisions alongside your clinical care team.